Alloantibody and crossmatch in simultaneous liver and kidney transplantation: Is the jury still out?
Brittany Rocque, Sean Martin, Juliet Emamaullee, Yong Kwon – 2 April 2022
Reply
Jennifer R. Kramer, Yamini Natarajan, Jianliang Dai, Xian Yu, Liang Li, Hashem B. El‐Serag, Fasiha Kanwal – 1 April 2022
Intestinal virome in patients with alcohol use disorder and after abstinence
Cynthia L. Hsu, Xinlian Zhang, Lu Jiang, Sonja Lang, Phillipp Hartmann, David Pride, Derrick E. Fouts, Peter Stärkel, Bernd Schnabl – 1 April 2022 – Alcohol use is a leading cause of chronic liver disease worldwide, and changes in the microbiome associated with alcohol use contribute to patients’ risk for liver disease progression. Less is known about the effects of alcohol use on the intestinal viral microbiome (virome) and interactions between bacteriophages and their target bacteria.
HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection
Michel Bazinet, Mark Anderson, Victor Pântea, Gheorghe Placinta, Iurie Moscalu, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Liviu Iarovoi, Valentina Smesnoi, Tatina Musteata, Alina Jucov, Ulf Dittmer, Jeff Gersch, Vera Holzmayer, Mary Kuhns, Gavin Cloherty, Andrew Vaillant – 1 April 2022 – Nucleic acid polymers block the assembly of hepatitis B virus (HBV) subviral particles, effectively preventing hepatitis B surface antigen (HBsAg) replenishment in the circulation.
Letter to the editor: Effect of diabetes medications and glycemic control on risk of HCC in patients with NAFLD
Yibing Zhou, Weike Chu, Xue Wu, Hui Zhou, Bin Niu, Ze Chen, Yuqiang Mi, Ping Li – 1 April 2022
Innate lymphoid cells at the crossroads of innate and adaptive immunity
Firouzeh Korangy, Bernd Heinrich, Tim F. Greten – 1 April 2022
Reply
Jessica Musto, Michael R. Lucey, John Rice – 31 March 2022
Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning
Mazen Noureddin, Fady Ntanios, Deepa Malhotra, Katherine Hoover, Birol Emir, Euan McLeod, Naim Alkhouri – 31 March 2022 – This cohort analysis investigated the prevalence of nonalcoholic fatty liver disease (NAFLD) and NAFLD with fibrosis at different stages, associated clinical characteristics, and comorbidities in the general United States population and a subpopulation with type 2 diabetes mellitus (T2DM), using the National Health and Nutrition Examination Survey (NHANES) database (2017–2018).
An international survey on patterns of practice in NAFLD and expectations for therapies—The POP‐NEXT project
Vlad Ratziu, Quentin M. Anstee, Vincent Wai‐Sun Wong, Jörn M. Schattenberg, Elisabetta Bugianesi, Salvador Augustin, Liana Gheorghe, Vittoria Zambon, Nancy Reau – 31 March 2022
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?
Zobair M. Younossi, James M. Paik, Reem Al Shabeeb, Pegah Golabi, Issah Younossi, Linda Henry – 31 March 2022